AnaptysBio ( ANAB ) Q2 Revenue Jumps 103%
AnaptysBio ( NASDAQ:ANAB ) , a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6, 2025. The company reported $22.3 million in collaboration revenue in Q2 2025, more than doubling ...
AnaptysBio, Inc. ( ANAB ) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
AC Immune ( ACIU ) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics ( NASDAQ:AVTX )
WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
AnaptysBio Upgraded After RA Drug Matches Top Therapies In Phase 2 Trial - AnaptysBio ( NASDAQ:ANAB )
69% of rosnilimab patients achieved low disease activity by Week 14; 83% remained in LDA at Week 34. All doses showed statistically significant ACR20 and DAS-28 CRP reductions at Week 12 vs placebo. Get access to the leaderboards pointing to tomorrow's biggest stock movers. AnaptysBio, Inc.
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May - AnaptysBio ( NASDAQ:ANAB ) , Asana ( NYSE:ASAN )
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday. The Dow traded up 0.09% to 42,558.84 while the NASDAQ rose 0.31% to 19,459.23. The S&P 500 also rose, gaining, 0.19% to 5,981.93. Communication services shares jumped by ...
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - AnaptysBio ( NASDAQ:ANAB ) , Blueprint Medicines ( NASDAQ:BPMC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Emily Bodnar upgraded the rating for AnaptysBio, Inc.
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday - AnaptysBio ( NASDAQ:ANAB ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of HEICO Corporation HEI rose sharply during Wednesday's session following better-than-expected quarterly results. Heico reported quarterly earnings of $1.12 per share which beat the analyst ...
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of ...
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc.
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn ( OTC:CYDY )
VANCOUVER, Washington, May 06, 2025 ( GLOBE NEWSWIRE ) -- CytoDyn Inc. CYDY ( "CytoDyn" or the "Company" ) , a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E.
AnaptysBio, Inc. ( ANAB ) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of 1.54% and 52.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, May 05, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
AnaptysBio ( ANAB ) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Crude Oil Gains 1%; US Composite PMI Surges In March - AnaptysBio ( NASDAQ:ANAB ) , AZEK Co ( NYSE:AZEK )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 350 points on Monday. The Dow traded up 1.35% to 42,551.10 while the NASDAQ climbed 2.08% to 18,119.66. The S&P 500 also rose, gaining, 1.66% to 5,761.78. Consumer discretionary shares jumped by 3.2% on ...
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday - AnaptysBio ( NASDAQ:ANAB ) , AZEK Co ( NYSE:AZEK )
U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Monday. Shares of Intuitive Machines, Inc. LUNR rose sharply during Monday's session following fourth-quarter results.
Anaptys Announces Stock Repurchase Plan
SAN DIEGO, March 24, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may ...
Anaptys Announces Stock Repurchase Plan - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, March 24, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to ...
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - AnaptysBio ( NASDAQ:ANAB ) , American Eagle Outfitters ( NYSE:AEO )
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Thursday. Shares of UiPath Inc. PATH fell sharply in today's pre-market trading after the company reported a fourth-quarter revenue miss and issued first-quarter revenue guidance below estimates.
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Aditxt ( NASDAQ:ADTX ) , American Eagle Outfitters ( NYSE:AEO )
Shares of Intel Corporation INTC rose sharply in today's pre-market trading after the company announced a new chief executive officer. The company said its board of directors has appointed Lip-Bu Tan, a former member of Intel's board of directors, as chief executive officer, effective March 18.
AnaptysBio, Inc. ( ANAB ) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Astrana Health, Inc. ( ASTH ) Reports Q4 Loss, Tops Revenue Estimates
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -266.67% and 5.42%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
SAN DIEGO, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business ...
Anaptys Announces Participation in March Investor Conferences
SAN DIEGO, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its ...
Anaptys Announces Participation in March Investor Conferences - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive ...
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
VANCOUVER, British Columbia, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
Is AnaptysBio ( ANAB ) Stock Outpacing Its Medical Peers This Year?
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
AnaptysBio ( ANAB ) Surges 30.5%: Is This an Indication of Further Gains?
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday - AnaptysBio ( NASDAQ:ANAB ) , Angi ( NASDAQ:ANGI )
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of Gilead Sciences, Inc. GILD rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above ...
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
SAN DIEGO, Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial ...
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc.
Molina Healthcare Q4 Earnings Miss Estimates on Growing Medical Costs
MOH expects total membership to be at 5.9 million by 2025-end.
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
SAN DIEGO, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim ...
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap ...
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
WASHINGTON and SAN DIEGO, Feb. 03, 2025 ( GLOBE NEWSWIRE ) -- Vanda Pharmaceuticals Inc. ( Vanda ) ( Nasdaq: VNDA ) and AnaptysBio, Inc. ( Anaptys ) ( Nasdaq: ANAB ) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ( IL-36R ...
Are Medical Stocks Lagging AnaptysBio ( ANAB ) This Year?
Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - AnaptysBio ( NASDAQ:ANAB ) , Associated Cap Gr ( NYSE:AC )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 150 points on Wednesday. Shares of Progress Software Corporation PRGS fell sharply in today's pre-market trading after the company issued first-quarter EPS guidance below estimates.
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - AnaptysBio ( NASDAQ:ANAB ) , Associated Cap Gr ( NYSE:AC )
Shares of Netflix, Inc. NFLX rose sharply in today's pre-market trading as the company reported stronger-than-expected fourth-quarter financial results. Netflix reported it added 18.91 million paid subscribers in the fiscal quarter, up 15.9% year-over-year.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
How AnaptysBio ( ANAB ) Stock Stands Out in a Strong Industry
AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Are Medical Stocks Lagging United Therapeutics ( UTHR ) This Year?
Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual ...
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P.
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
Why Is AnaptysBio Stock Plunging Today? - AnaptysBio ( NASDAQ:ANAB )
On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis ( AD ) or eczema.
Is Siga Technologies ( SIGA ) Stock Outpacing Its Medical Peers This Year?
Here is how Siga Technologies Inc. (SIGA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
